Back to top
more

Boston Scientific (BSX)

(Delayed Data from NYSE)

$104.83 USD

104.83
4,831,663

-1.96 (-1.84%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $104.84 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (155 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).

Zacks Equity Research

Is it Worth Adding Boston Scientific Stock to Your Portfolio Now?

by Zacks Equity Research

BSX rides on strong MedSurg growth and strategic acquisitions amid currency headwinds.

Zacks Equity Research

AMN Stock Gains Post Latest Deals With symplr to Boost Operations

by Zacks Equity Research

AMN Healthcare sells Smart Square to symplr for $75 million and forms a new technology partnership aimed at boosting scheduling efficiency.

Zacks Equity Research

Boston Scientific (BSX) Suffers a Larger Drop Than the General Market: Key Insights

by Zacks Equity Research

In the most recent trading session, Boston Scientific (BSX) closed at $102.41, indicating a -1.37% shift from the previous trading day.

Kinjel Shah headshot

Will J&J's Q2 Results Reflect End of MedTech Issues & Higher Sales?

by Kinjel Shah

JNJ's MedTech unit eyes second-half growth despite China headwinds, U.S. competition and tariff pressure.

Zacks Equity Research

Teleflex Acquires BIOTRONIK's Vascular Intervention Business, Stock Up

by Zacks Equity Research

TFX gains 2.9% after acquiring BIOTRONIK's vascular unit, boosting its cath lab presence and innovation pipeline.

Zacks Equity Research

Will Boston Scientific (BSX) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Boston Scientific (BSX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

Boston Scientific Climbs 40.5% in a Year: What's Driving the Stock?

by Zacks Equity Research

BSX rallies 40.5% in a year, fueled by WATCHMAN growth, MedSurg gains, acquisitions and global expansion efforts.

Zacks Equity Research

PAHC vs. BSX: Which Stock Is the Better Value Option?

by Zacks Equity Research

PAHC vs. BSX: Which Stock Is the Better Value Option?

Zacks Equity Research

Bio-Techne's New USP Deal on mAb and Gene Therapy May Boost Its Stock

by Zacks Equity Research

TECH teams up with USP to boost mAb and gene therapy testing, aiming to simplify analytics and enhance product quality.

Zacks Equity Research

Boston Scientific (BSX) Surpasses Market Returns: Some Facts Worth Knowing

by Zacks Equity Research

Boston Scientific (BSX) reached $106.53 at the closing of the latest trading day, reflecting a +1.86% change compared to its last close.

Kinjel Shah headshot

J&J's MedTech Segment Slowing Down: Will its Sales Recover in 2025?

by Kinjel Shah

JNJ's MedTech sales face pressure from China and competition but new products may lead to a stronger second half of 2025.

Sridatri Sarkar headshot

BSX vs. MDT: Which MedSurg Stock Is the Better Investment Now?

by Sridatri Sarkar

As MedSurg demand rises, Boston Scientific and Medtronic compete for dominance. Which stock shows stronger growth momentum now?

Zacks Equity Research

Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings

by Zacks Equity Research

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Zacks Equity Research

Teladoc (TDOC) Moves 14.4% Higher: Will This Strength Last?

by Zacks Equity Research

Teladoc (TDOC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks Equity Research

Exelixis (EXEL) Surges 7.4%: Is This an Indication of Further Gains?

by Zacks Equity Research

Exelixis (EXEL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks Equity Research

Strength Seen in Nektar (NKTR): Can Its 12.1% Jump Turn into More Strength?

by Zacks Equity Research

Nektar (NKTR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks Equity Research

Are Business Services Stocks Lagging GORILLA TECH GP (GRRR) This Year?

by Zacks Equity Research

Here is how Gorilla Technology Group Inc. (GRRR) and Healthcare Services (HCSG) have performed compared to their sector so far this year.

Zacks Equity Research

Are Utilities Stocks Lagging Entergy (ETR) This Year?

by Zacks Equity Research

Here is how Entergy (ETR) and Innergex (INGXF) have performed compared to their sector so far this year.

Zacks Equity Research

Is Air Lease (AL) Stock Outpacing Its Transportation Peers This Year?

by Zacks Equity Research

Here is how Air Lease (AL) and Grupo Aeroportuario del Sureste (ASR) have performed compared to their sector so far this year.

Zacks Equity Research

Is GRINDR INC (GRND) Stock Outpacing Its Computer and Technology Peers This Year?

by Zacks Equity Research

Here is how Grindr Inc. (GRND) and Nutanix (NTNX) have performed compared to their sector so far this year.

Zacks Equity Research

Are Aerospace Stocks Lagging CurtissWright (CW) This Year?

by Zacks Equity Research

Here is how Curtiss-Wright (CW) and Huntington Ingalls (HII) have performed compared to their sector so far this year.

Zacks Equity Research

Is Axos Financial (AX) Stock Outpacing Its Finance Peers This Year?

by Zacks Equity Research

Here is how Axos Financial (AX) and Banco Santander-Chile (BSAC) have performed compared to their sector so far this year.

Zacks Equity Research

Is Douglas Dynamics (PLOW) Outperforming Other Auto-Tires-Trucks Stocks This Year?

by Zacks Equity Research

Here is how Douglas Dynamics (PLOW) and Ferrari (RACE) have performed compared to their sector so far this year.

Zacks Equity Research

Are Basic Materials Stocks Lagging CF Industries (CF) This Year?

by Zacks Equity Research

Here is how CF Industries (CF) and Gold Fields (GFI) have performed compared to their sector so far this year.

Zacks Equity Research

Are Consumer Discretionary Stocks Lagging Atour Lifestyle Holdings Limited Sponsored ADR (ATAT) This Year?

by Zacks Equity Research

Here is how Atour Lifestyle Holdings Limited Sponsored ADR (ATAT) and Grand Canyon Education (LOPE) have performed compared to their sector so far this year.